Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference
Invivyd (Nasdaq: IVVD) has announced its participation in the upcoming Guggenheim Securities Healthcare Innovation Conference in Boston, MA. The company's management will engage in a fireside chat scheduled for Wednesday, November 13, 2024, at 2:30 PM ET, along with conducting one-on-one investor meetings during the conference, which runs from November 11-13, 2024.
A live webcast of the presentation will be accessible through the investor section of Invivyd's website and will remain available for approximately 30 days after the event.
Invivyd (Nasdaq: IVVD) ha annunciato la sua partecipazione alla prossima Guggenheim Securities Healthcare Innovation Conference a Boston, MA. La direzione dell'azienda parteciperà a un colloquio informale previsto per mercoledì 13 novembre 2024, alle 14:30 ET, e svolgerà incontri individuali con gli investitori durante la conferenza, che si terrà dal 11 al 13 novembre 2024.
Una trasmissione in diretta della presentazione sarà disponibile nella sezione investitori del sito web di Invivyd e rimarrà accessibile per circa 30 giorni dopo l'evento.
Invivyd (Nasdaq: IVVD) ha anunciado su participación en la próxima Guggenheim Securities Healthcare Innovation Conference en Boston, MA. La dirección de la empresa participará en una conversación de tipo fireside programada para el miércoles 13 de noviembre de 2024, a las 2:30 PM ET, y llevará a cabo reuniones individuales con inversores durante la conferencia, que se desarrollará del 11 al 13 de noviembre de 2024.
Una transmisión en vivo de la presentación estará disponible a través de la sección de inversores en el sitio web de Invivyd y permanecerá accesible durante aproximadamente 30 días después del evento.
Invivyd (Nasdaq: IVVD)가 매사추세츠주 보스턴에서 열리는 Guggenheim Securities Healthcare Innovation Conference에 참여한다고 발표했습니다. 회사의 경영진은 2024년 11월 13일 수요일 오후 2시 30분 ET에 예정된 대화형 세션에 참석하며, 회의 기간인 2024년 11월 11일부터 13일까지 투자자와의 일대일 미팅도 진행할 예정입니다.
발표의 실시간 방송은 Invivyd의 웹사이트 투자자 섹션을 통해 제공되며, 이벤트 이후 약 30일 동안 시청할 수 있습니다.
Invivyd (Nasdaq: IVVD) a annoncé sa participation à la prochaine Guggenheim Securities Healthcare Innovation Conference à Boston, MA. La direction de l'entreprise participera à une discussion conviviale prévue pour le mercredi 13 novembre 2024, à 14h30 ET, tout en organisant des réunions individuelles avec des investisseurs pendant la conférence, qui se déroulera du 11 au 13 novembre 2024.
Une diffusion en direct de la présentation sera accessible via la section investisseurs du site web de Invivyd et restera disponible pendant environ 30 jours après l'événement.
Invivyd (Nasdaq: IVVD) hat seine Teilnahme an der kommenden Guggenheim Securities Healthcare Innovation Conference in Boston, MA, bekannt gegeben. Das Management des Unternehmens wird sich an einem sogenannten Fireside Chat beteiligen, der für Mittwoch, den 13. November 2024, um 14:30 Uhr ET geplant ist, und wird während der Konferenz, die vom 11. bis 13. November 2024 stattfindet, Einzelgespräche mit Investoren führen.
Ein Live-Stream der Präsentation wird über den Investorenbereich der Invivyd-Website verfügbar sein und bleibt etwa 30 Tage nach der Veranstaltung zugänglich.
- None.
- None.
WALTHAM, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that management will participate in a fireside chat and 1x1 investor meetings at the Guggenheim Securities Healthcare Innovation Conference taking place November 11-13, 2024.
Fireside Chat: Wednesday, November 13, 2024 at 2:30 PM ET
Location: Boston, MA
The live webcast link will be available in the investor section of the company's website at https://investors.invivyd.com and will be archived for approximately 30 days following the event.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
Contacts:
Media Relations
(781) 208-1747
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com
FAQ
When is Invivyd (IVVD) presenting at the Guggenheim Securities Healthcare Conference 2024?
Where can I watch Invivyd's (IVVD) Guggenheim Securities Conference presentation?
What type of meetings will Invivyd (IVVD) conduct at the Guggenheim Healthcare Conference?
How long will Invivyd's (IVVD) Guggenheim Conference presentation be available online?
